Insights

The High Cost of RA Infusions – and How Leap Fixes It

Image

Rheumatoid arthritis (RA) is a debilitating autoimmune disease that requires ongoing treatment to manage inflammation, pain and joint damage. For many patients, biologic infusions such as Remicade, Actemra, and Orencia are essential but they come at an enormous cost, often due not just to the drug itself but also to the site of service.

Why Are RA Infusions So Expensive?

The cost of an RA infusion can vary drastically based on where it’s administered:

  • Hospital-based infusions can be marked up by as much as 500%.
  • Ambulatory infusion centers (AICs) still add a 50% markup.
  • Home infusion eliminates these markups, saving thousands per treatment.

And the impact is significant:

  • Higher Costs: RA patients receive seven infusions per year on average and, according to a SHRM study,  incur approximately $4,687 more in annual medical and rx spend than other employees.
  • Increased Absenteeism: On average, employees with RA take an additional 3.58 days off per year, including 1.2 more sick leave days and 1.91 more short-term disability days, leading to higher indirect costs.
  • Overall Economic Burden: According to SHRM, RA contributes to 172 million lost workdays and $304 billion in combined medical costs and lost earnings annually in the United States. 

For employers, these inflated costs aren’t just a burden—they’re avoidable.

How Leap Saves Employers $24,000 Per RA Patient

Leap eliminates unnecessary markups through pass-through pricing, ensuring that employers and patients pay only the true drug cost. With Leap: 

  • No hidden fees or inflated provider charges
  • A nationwide specialty pharmacy network securing lower pricing
  • Home infusion options that cut costs even further

Average employer savings per patient = $3,500 per treatment / $24,000 annually

The Bottom Line

RA patients shouldn’t have to navigate financial roadblocks just to stay mobile and pain-free. With Leap, infusion therapy is both affordable and accessible—helping employers save millions while ensuring their employees receive the care they need.

Share this post

More insights

Image
Education

The Infusion Cost Crisis: Why Medical Benefit Drug Spend Keeps Escalating

For employers, however, infusion care has quietly become one of the fastest-growing and least unders...

Read article
Image
News

Leap Joins the Castlight Ecosystem to Simplify Infusion Care

Leap has joined the Castlight ecosystem to give TPAs and employers a more transparent, predictable, ...

Read article
Image
Insights

Rebates, what rebates? Understanding pharmacy rebates for J-Code drugs

Pharmacy rebates are manufacturer-paid discounts, typically negotiated behind

Read article
Image
Education

Demystifying Specialty Drug Pricing Acronyms, and Why They All Fail Employers

Behind the exorbitant costs of infusion therapies, you’ll find layers of complexity—and three acrony...

Read article
Image
Clinical

Safely Infusing Immunoglobulin in the Home Setting: Clinical Considerations and Best Practices

Immunoglobulin (Ig) therapies are essential in the treatment of primary immunodeficiency (PID), chro...

Read article
Image
News

Leap and Amwins Partner to Deliver Low-Cost, Convenient Infusion Therapy

Leap and Amwins Rx, today announced a strategic collaboration that will bring significant benefits t...

Read article
Image
Case Study

Bringing Relief Home for Annie

Helping a working parent stay on track with infusion care

Read article
Image
Insights

How Leap Reduces the Total Cost of Multiple Sclerosis Care

For patients requiring long-term MS infusions like Ocrevus or Tysabri, traditional hospital-based tr...

Read article
Image
News

Leap and Blackhawk Claims Service Partner to Reduce Specialty Medication Costs and Improve Patient Access

We're so excited to announce our strategic partnership with Blackhawk Claims Service, a leading thir...

Read article
Image
Insights

Why Home Infusion Is Safe, Effective – and Preferred by Patients

More patients and employers are choosing home infusion as a safe, effective alternative to hospital-...

Read article